Tonix Pharmaceuticals replaces EisnerAmper with PwC as independent auditor

Reuters
03/18
Tonix Pharmaceuticals replaces EisnerAmper with PwC as independent auditor

Tonix dismissed EisnerAmper as its independent registered public accounting firm on March 16, 2026. The audit committee approved the change, and Tonix said the dismissal was not related to disagreements on accounting principles, financial statement disclosure, or auditing scope. EisnerAmper’s audit reports for fiscal 2025 and 2024 included a going-concern explanatory paragraph tied to continuing losses and negative operating cash flows. Tonix appointed PwC as its new independent registered public accounting firm for fiscal 2026 and related interim periods on March 16, 2026. Tonix said it had not consulted with PwC on accounting or audit opinion matters during fiscal 2025, fiscal 2024, or the interim period through the engagement date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001999371-26-006169), on March 18, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10